EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026.03.23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026.03.23

Date

Title

2021-07-19

First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-04-30

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting

2021-04-20

Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia

2021-04-07

Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercialisation in China

2021-03-19

Essex-Biotechnology Announces Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD

2021-03-12

Essex Bio-Technology Announces 2020 Financial Results Sales of HK$654m & PAT of HK$170m recorded in 2nd Half

2021-02-24

Essex Bio-Technology and Mitotech announce positive outcome of VISTA-2 Phase 3 clinical study in Dry Eye Disease

2021-01-29

Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT